Michael Tarnow, Chairman
Mr. Tarnow was appointed chairman of our Board in February 2003. Since 1995, Mr. Tarnow has been an advisor to and member of the boards of directors of several healthcare-related organizations in the U.S., Canada and Europe, including publicly traded companies Axcan Pharma, Inc., Thallion Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. He also serves on the Boards of the University of Illinois College of Law, Massachusetts College of Art Foundation and the Food Drug Law Institute. From 1995-2000, he was President and CEO of Boston-based Creative BioMolecules, Inc. Prior to that, he spent 22 years at Merck & Co., Inc., where he served in a wide variety of positions including heading corporate development, President and CEO of Merck Frosst Canada and Executive Vice President of Merck-Medco.

James S. Burns
Mr. Burns has been President and Chief Executive Officer of the Company since June 2004 and a Director since September 2004. From 2001-2003, Mr. Burns was a co-founder and served as President and as Executive Vice President of MedPointe, Inc. From 2000-2001, he served as a founder and Managing Director of MedPointe Capital Partners, a private equity firm that led a leveraged buyout to form MedPointe Pharmaceuticals. Mr. Burns’ experience includes serving as chairman, president and CEO of Osiris Therapeutics, Inc., vice chairman of HealthCare Investment Corporation, founding general partner of Healthcare Ventures L.P., group president at Becton Dickinson, and vice president and partner at Booz Allen & Hamilton, Inc. Mr. Burns currently is chairman of the executive committee of the American Type Culture Collection (ATCC), a director of Symmetry Medical, Inc., and a director of Ciphergen Biosystems, Inc.

Donald S. Brooks
Mr. Brooks has been a Director of the Company since April 1996 and was Vice President, Legal Affairs of the Company from 1998 until August 2001. Between 2001 and 2004, Mr. Brooks served as a consultant to the Company. Prior to that, Mr. Brooks was a practicing attorney and was previously employed by Merck and Co. for 27 years in various business and legal capacities. He currently serves as a member of the Board of Directors of BioDiem, Ltd., an Australian biotechnology company. In addition, he recently served as a director of Xenon Pharmaceuticals, Inc., a Canadian biotechnology firm, and currently acts as a consultant to that company.

Dwight L. Bush, Sr.
Mr. Bush has been a Director of the Company since June 2004. Mr. Bush has been President & CEO of Urban Trust Bank and Urban Trust Holdings since March 2006 and President of UTB Education Finance, LLC since June 2006. From 2002-2006, Mr. Bush was a principal in an Arlington-based investment firm and prior to that served in various financial and management roles in financial institutions. Mr. Bush currently serves on the Board of Trustees of Cornell University, the GAVI Fund, and The National Symphony Orchestra.

Ronald Cape, PhD
Dr. Cape has been a Director of the Company since 2003. Since 199l, he has been an investor in the field of biotechnology and a board member of various companies. Dr. Cape is the founder of Ronald Cape Investment Management, LLC, a consulting firm and was the co-founder and former chairman of Cetus Corporation. He is currently a director of Neurobiological Technologies, Inc., Caprion, Inc., Neugenesis Corp. and PureTech Ventures LLC. He was also a founding member of the Biotechnology Industry Organization and served as its president for three years.

Jennie Hunter-Cevera, PhD
Dr. Hunter-Cevera has been a Director of the Company since June 2001. Dr. Hunter-Cevera is the President of the University of Maryland Biotechnology Institute. Prior to joining the University of Maryland in October 1999, Dr. Hunter-Cevera had been the head of the Center for Environmental Biotechnology at Lawrence Berkeley National Laboratory between November 1994 and October 1999, Director of Fermentation, Research and Development at Cetus Corporation and a scientist at E.R. Squibb and Company. She was co-founder of The Biotic Network and Blue Sky Laboratories in Sonora, CA. Dr. Hunter-Cevera was elected to the American Academy of Microbiology in 1995, the recipient of the 1996 SIM Charles Porter Award, elected as a SIM Fellow in 1997 and the 1999 Nath Lecturer at West Virginia University. She is the 2004 recipient of the ASM Porter Award for achievement in biodiversity research.

Peter S. Knight
Mr. Knight has been a Director of the Company since June 2000. Mr. Knight has been President of Generation Investment Management US, a London-based asset management company, since August 2004. From 2001-2003, he was a Managing Director of MetWest Financial. Prior to that, Mr. Knight’s business experience included serving as general counsel of Medicis Pharmaceutical and a practicing attorney. Mr. Knight’s experience also includes serving as chief of staff to Al Gore when Mr. Gore was a member of the U.S. House of Representatives and later the U.S. Senate and holding senior positions with four presidential campaigns, including serving as campaign manager for the successful 1996 re-election of President Clinton. Mr. Knight currently serves as a director of Medicis Pharmaceutical Corp. and Par Pharmaceuticals. He is also a director of Schroders’ mutual fund and hedge fund family, a member of the Cornell University College of Arts and Sciences Advisory Council, and the Johnson Schools Center for Sustainable Global Enterprise.

Mark C. M. Randall
Mr. Randall has been a Director of the Company since April 1996. He has been CEO of Commander Asset Management Ltd. since May 2002. Prior to this appointment, he was associated with Sarasin International Securities Limited, a wholly owned subsidiary of Bank Sarasin and Cie, a private bank based in Switzerland, where he was a director and later a managing director.